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INTRODUCTION
Endocrine therapy has been considered the most important 
systemic therapy for all stages of hormone-receptor-positive 
breast cancers for more than 100 years. A major clinical prob-
lem limiting the usefulness of this therapy is resistance [1]. In 
the metastatic setting especially, initially responsive tumors 
eventually become resistant to endocrine treatment, leading to 
tumor progression and death [2]. Therefore, extensive basic 
and clinical research is aimed at differentiating breast cancer 
patients into subgroups with predictable clinical outcomes. 
Pathological separation of breast cancers based on tumor grade 
and stage provides primary information on disease outcomes, 
but this information falls short of the accurate outcome pre-
diction required in clinics. The status of hormone receptors 
including estrogen receptor (ER)-alpha and progesterone re-
ceptor (PR) are known to be good prognostic and predictive 
markers for endocrine therapy for breast cancer. For many 
years, only one gene for ER, ER-alpha, had been recognized 
and was known to correlate with prognosis. ER-alpha-positive 
tumors are frequently treated with anti-estrogen drugs such as 
tamoxifen and aromatase inhibitors and usually have better 
prognoses than do ER-alpha-negative tumors [3], but in 1996, 
a second ER subtype, ER-beta, was identified [4]. ER-beta 
showed strong homology with ER-alpha in the DNA-binding 
domain and the ligand-binding domain, but little elsewhere 
[5]. Several groups have investigated the expression of ER-beta 
using real-time polymerase chain reaction (RT-PCR) [6] and 
immunohistochemistry or Western blotting [7,8]. However, 
the results have been rather inconsistent. Further, predictive or 
prognostic significance of expression of ER-beta protein or 
mRNA is still controversial.
In this study, we investigated ER-beta mRNA using the 
branched chain QuantiGene2.0 assay, the respective protein 
expression (ER-beta), ER-alpha, and PR using immunohisto-
chemistry (IHC), the status of the HER2 gene by silver in situ 
hybridization (SISH) in surgically treated ER-positive breast 
cancer following endocrine therapy. We examined their rela-
tionships with clinicopathological factors and prognosis.
METHODS
Patients
Of the patients with invasive breast carcinoma, 139 samples 
Prognostic Significance of High Expression of ER-beta in Surgically Treated 
ER-Positive Breast Cancer Following Endocrine Therapy
Tae-Jung Kim, Ahwon Lee, Yeong-Jin Choi, Byung Joo Song
1, Hyeon Woo Yim
2, Chang Suk Kang
Departments of Hospital Pathology,
 1Surgery, and
 2Preventive Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
ORIGINAL ARTICLE
J Breast Cancer 2012 March; 15(1): 79-86  http://dx.doi.org/10.4048/jbc.2012.15.1.79
Purpose: This study evaluated estrogen receptor (ER)-beta mRNA 
and ER-beta protein expression and its prognostic implications 
in hormone receptor-positive breast cancer. Methods: Paraffin 
sections from 139 hormone receptor-positive breast cancer cases 
were prepared. The expression of ER-beta mRNA and protein 
were analyzed by branched-chain assay and immunohistochem-
istry (IHC), respectively. Results: The Allred score of ER-beta IHC 
was correlated with smaller tumor size (p=0.043), the Allred 
score of ER-alpha IHC (p<0.001), and the Allred score of pro-
gesterone receptor (PR) IHC (p=0.022) but not with the HER2 
IHC score. ER-beta mRNA level was correlated with PR mRNA 
levels (p<0.001) but not with the Allred score of ER-beta IHC, 
ER-alpha IHC, and PR IHC, nor with the HER2 IHC score and 
ER-alpha mRNA level. In survival analysis, high expression of 
ER-beta mRNA was associated with worse disease-free survival 
along with poor differentiation, lymph node metastasis and ab-
sence of PR protein expression in univariate analysis (p=0.040, 
p=0.002, p=0.018, and p=0.007, respectively) and multivariate 
analysis (p=0.044, p=0.002, p=0.035, and p=0.007, respec-
tively). Conclusion: High expression of ER-beta mRNA is an inde-
pendent predictor of disease recurrence in hormone-receptor-
positive breast cancer.
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were collected from patients who underwent breast cancer 
surgery following treatment with endocrine therapy accord-
ing to the ER-positive result and had long-term follow-up in-
formation between January 2003 and December 2005 at Seoul 
St. Mary’s Hospital. All cases were stage I, II, or III and diag-
nosed as invasive carcinoma based on the core-biopsy. Histo-
logic types (130 invasive ductal carcinomas, not otherwise 
specified; 5 mucinous carcinomas; 3 lobular carcinomas; and 
a tubular carcinoma) were verified on paraffin-embedded 
slides after operation by two pathologists. All patients under-
went local and systemic treatments. Local treatment included 
surgery and radiotherapy. Systemic treatment included chemo- 
therapy and endocrine therapy according to routine institu-
tional protocol, and none of the patients received neoadjuvant 
chemotherapy. Surgical procedures consisted of mastectomy 
and breast conserving surgery. We retrospectively reviewed 
follow-up data. The follow-up contacts were carried out at 3- 
month intervals over the first year, 6-month intervals during 
the second year, and at 12-month intervals thereafter. The med-
ical work-up consisted of regular physical checkups. Imaging 
tests such as X-ray, positron emission tomography, bone scan, 
and/or ultrasound were used to look for recurrences, second 
primary breast cancers, or metastatic disease. Recurrence was 
defined as radiographic or pathological evidence of regional 
tumor recurrence or distant metastasis at any time after initial 
therapy. Overall survival time was defined as the interval be-
tween the date of histological confirmation of disease and death 
or the last observation taken. The data were censored at the 
last follow-up period for living patients. Disease-free survival 
time was calculated as the time that recurrence was first sus-
pected. In disease-free survival analysis, the data were censored 
for patients without tumor recurrence. The data of ER-alpha 
mRNA levels and PR mRNA levels measured by a branched-
chain assay were obtained from previous study [9]. Study de-
sign, data collection, and analysis followed the principles of 
the Declaration of Helsinki. This study was approved by the 
Institutional Review Board (IRB) of the Catholic University of 
Korea (IRB number, KC11TISI0143).
Tissue microarray
To construct the tissue microarray block, a 2 mm-sized sin-
gle core was taken from morphologically representative areas 
of formalin-fixed and paraffin-embedded (FFPE) tumor tis-
sue and were assembled on a premade recipient block (con-
taining 6 holes by 10 holes) using a manual tissue arrayer 
(Quick-Ray Manual Tissue Microarrayer; Unitma Co., Ltd., 
Seoul, Korea). After construction, one section was stained 
with hematoxylin and eosin for histology verification. Each of 
the recipient blocks had 2 different control cores of normal 
breast tissue obtained from breast reduction surgery. 
Immunohistochemistry
For ER-beta staining, sections of the FFPE tissue arrays were 
deparaffinized and quenched with 3% hydrogen peroxide. 
Heat-induced epitope retrieval was conducted by boiling the 
slides in a 0.01 M citrate buffer (pH 6.0) using a microwave 
vacuum histoprocessor (RHS-1; Milestone, Bergamo, Italy) at 
a temperature of 121°C for 15 minutes. The sections of tissue 
array were incubated with monoclonal ER-ß antibody (1:50; 
Santa Cruz Biotechnology, Santa Cruz, USA) at room tem-
perature for 30 minutes followed by incubation with peroxi-
dase labeled polymer conjugated to secondary antibody 
(EnVision
TM+Kit, DAKO, Carpinteria, USA) for 30 minutes. 
The immunoreactions were visualized with 3-3’-diaminoben-
zidine (DAB) and counterstained with Mayer’s hematoxylin. 
For ER and PR staining, all procedures were performed     
using an Ventana BenchMark
®XT automated slide stainer 
(Ventana, Tuscon, USA), with anti-ER (SP1) rabbit monoclo-
nal antibody (Ventana) and anti-PR (clone 1E2) rabbit mono-
clonal antibody (Ventana).
The Allred scoring system [10] was used for ER, PR, and 
ER-beta staining interpretation. The proportion of positive 
stained cells was rated as follows: 0, no cells stained positive; 1, 
between 0% and 1% positive; 2, between 1% and 10% positive; 
3, between 10% and 33% positive; 4, between 33% and 66% 
positive; and 5, between 66% and 100% positive. In addition 
to the proportion score, an intensity score was made on the 
basis of the average intensity of staining: 0, negative; 1, weak; 2, 
intermediate; and 3, strong. The intensity score and the pro-
portion score were added to obtain the total score; this is re-
ferred to as the Allred score [10], and is either 0 or between 2 
and 8. Scores of 0 and 2 were interpreted as negative.
HER2 SISH 
Three-micrometer sections of the tissue arrays were stained 
according to the manufacturer’s protocols with the INFORM 
HER2 DNA probes (Ventana). The probe was labeled with di-
nitrophenol (DNP) and optimally formulated for use with the 
ultraView SISH Detection Kit and the Ventana BenchMark
®XT 
automated slide stainer (Ventana). The black dot signals for 
the HER2 gene were counted in at least 20 tumor cells and 
classified into 3 categories according to the 2007 American 
Society of Clinical Oncology/College of American Patholo-
gists (ASCO/CAP) [11]: The ratio of HER2⁄chromosome 17 
was then calculated by dividing the total score for HER2 by 
the total score for chromosome 17. 1) Negative for HER2 gene 
amplification, a ratio of <1.8; 2) positive for HER2 gene am-
plification, a ratio of >2.2; 3) equivocal, a ratio between 1.8 ER-betainHormoneReceptorPositiveBreastCancer 81
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and 2.2, For equivocal cases, signals from 20 more tumor nu-
clei were counted in each slide and a new ratio was calculated. 
This could be repeated in these border line cases until a clear 
decision was reached.
The branched chain QuantiGene2.0 assay
Tissue homogenates were prepared according to the proce-
dure described in the QuantiGene sample-processing kit for 
FFPE tissues (Panomics Inc., Fremont, USA). Briefly, from a 7 
μm-slide section, a total of 200 mm
2 of tumor area was selec-
tively dissected and incubated for 3 hours after adding 900 µL 
of homogenizing solution and 9 µL of proteinase K (50 µg/
µL). The tissue homogenate was separated from paraffin and 
debris by centrifugation and transferred to a fresh microfuge 
tube.
Probe design software was used to design specific oligonu-
cleotide probe sets for target genes to be used in Quantigene2.0 
reagent systems (Panomics Inc.). A probe set for a target gene 
consists of capture extenders, label extenders, and blocking 
probes, covering a continuous legion (1435-1813) of the ER-
beta transcript (whole length 2169). The Quantigene2.0 assay 
was performed according to the recommended protocol of 
Quantigene2.0 reagent systems, as previously described [9,12].
Statistical analysis 
All statistical analyses were performed using SPSS version 
13.0 (SPSS Inc., Chicago, USA) for Windows. Fisher’s exact 
probability test or the chi-square test was used to compare the 
mRNA and protein data for ER-beta with other clinicopatho-
logical variables. The correlation between the IHC data and 
RNA levels was evaluated using the Spearman correlation test. 
Survival curves were plotted using the Kaplan-Meier method, 
and the statistical significance was determined by the log-rank 
test. Multivariate Cox proportional hazards regression analy-
sis was performed to obtain a model for prognostic factors us-
ing backward selection strategies. p-values of less than 0.05 
Figure 1. Estrogen receptor (ER)-beta, ER-alpha, and progesterone receptor (PR) immunohistochemistry (IHC) results in breast carcinomas showed 
examples of positive nuclear staining of (A) ER-beta (×200), (B) ER-alpha (×200), and (C) PR (×200). HER2 silver in situ hybridization (SISH) results 
showed (D, E) the examples of HER2 amplification in SISH (D, HER2; E, chromosome 17; HER2/chromosome 17 ratio >2.2) (×400).
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were considered significant. Using receiver operating charac-
teristic (ROC) curve, we get the area under the ROC curve 
(AUC) to determine the cutoff value.
RESULTS
The positive rates for ER-beta and PR were 81.4% and 86.4%, 
respectively. HER2 amplification was observed in 8.6% (12 
out of 139 cases) (Figure 1). The Allred score for ER-beta IHC 
correlated with the Allred score for ER-alpha IHC (p<0.001, 
r=0.297) and the Allred score for PR IHC (p=0.022, r=0.195) 
but not with the HER2 IHC score (p=0.242, r=1.000) (Figure 2). 
ER-beta mRNA level by a QuantiGene2.0 assay ranges from 
0 to 1,826.1 (mean, 30.49). ER-beta mRNA level was not cor-
related with the Allred score of ER-beta IHC (p=0.480, r= 
0.060), ER-alpha IHC (p=0.463, r=-0.063), and PR IHC (p= 
0.736, r=0.029) nor with the HER2 IHC score (p=0.116, r= 
0.134) (Figure 3). ER-beta mRNA level was correlated with 
PR mRNA level (p<0.001, r=0.427) but not with ER-alpha 
mRNA level (p=0.097, r=0.141) (Figure 4). To identify a 
clinically meaningful cutoff point for levels of ER-beta mRNA 
expression that could be used in disease prognosis analysis, 
various levels of ER-beta mRNA expression were tested using 
the Kaplan-Meier method and verified by the log-rank test. 
Using the ROC curve, the cutoff value of ER-beta mRNA set 
at 0.29 showing sensitivity, and the specificity were 86.7% and 
41.1%, respectively, allowing us to obtain the most significant 
difference between the patient groups in disease-free survival 
analysis. And, the AUC was 0.659 with the p-value of 0.045 
(95% confidence interval, 0.525-0.793). ER-beta mRNA status 
was assessed as either low expression (0-2.9) or high expres-
sion (>2.9) using the cutoff level described above. High ER-
beta mRNA expression was observed in 62.1% of cases (87 
out of 139 cases). ER-beta IHC positivity was associated with 
smaller tumor size (p=0.045). In contrast to ER-beta IHC, 
there was no significant association between ER-beta mRNA 
expression and clinicopathological variables (Table 1).
During the median follow-up of 48 months (range, 5-74 
months), 15 patients (10.8%) experienced disease recurrence 
and 4 patient’s deaths (2.9%). In survival analysis, poor differ-
Figure 2. Plot error bar graph (mean, standard deviation, 95% confi-
dence interval), correlation between immunohistochemical staining re-
sults of (A) ER-beta versus ER-alpha, (B) ER-beta versus PR, and (C) 
ER-beta versus HER2.
ER=estrogen receptor; PR=progesterone receptor; IHC=immunohisto- 
chemistry.
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entiation (p=0.002), lymph node metastasis (p=0.019), Stage 
(III) (p=0.019), high expression of ER-beta mRNA (p=0.040) 
(Figure 5), and absence of PR protein expression (p=0.007) 
were associated with shorter disease-free survival in univari-
ate analysis. Age (≥50 year), poor differentiation, and lymph 
node metastasis tended to show worse overall survival but 
were not statistically significant (Table 2). Poor differentiation 
(hazard ratio [HR], 5.967; 95% confidence interval [CI], 1.939- 
18.365; p=0.002), lymph node metastasis (HR, 3.985; 95% CI, 
1.103-14.392; p=0.035), high expression of ER-beta mRNA 
(HR, 4.640; 95% CI, 1.039-20.727; p=0.044), and absence of 
PR protein expression (HR, 5.717; 95% CI, 1.712-19.092; p= 
0.005) were also independently associated with shorter dis-
ease-free survival in multivariate analysis (Table 3).
DISCUSSION
Breast cancer is a typical hormone-dependant tumor. It has 
been shown that longer exposure to estrogen results in an in-
creased risk of developing breast cancer, and endogenous es-
trogens are thought to play a major role in breast cancer carci-
nogenesis [13].
The accurate assessment of hormonal status is of therapeu-
tic importance because endocrine therapy reduces risk of re-
currence by more than 50% in breast cancer patients with 
hormone-sensitive tumors [14]. The current method used to 
determine breast cancer treatment is based on the evaluation 
of ER-alpha and PR gene status by IHC. ER-beta status could 
provide additional information about the therapeutic effect 
on or the prognostic value in breast cancer treated by various 
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Table 1. Distribution of ER-beta protein and mRNA status in surgically 
treated ER-positive breast cancer following endocrine therapy
Characteristics
ER-beta protein ER-beta mRNA
Negative Positive p-value Low  High  p-value
Age (yr)
  <50 11 57 0.454 26 43 1.000
  ≥50 15 56 27 44
Histologic type
   IDC 26 104 0.529 48 83 0.425
   ILC 0 3 2 1
   Mucinous ca 0 5 3 2
   Tubular ca 0 1 0 1
Differentiation
   Well 5 35 0.898 17 23 0.758 
   Moderate 16 55 26 45
   Poor 5 23 10 19
Size (cm)
  ≤2 11 74 0.045 30 56 0.376
  >2 15 39 23 31
Lymph node sta-
tus
   Negative 10 58 0.237 25 44 0.213 
   N1 11 35 20 26
   N2 3 16 8 11
   N3 2 4 0 6
AJCC stage
   I 6 45 0.256 20 32 0.794
   II 15 48 25 38
   III 5 20 8 17
HER2 SISH
   Not amplified 25 103 0.465 50 78 0.535
   Amplified 1 11 3 9
ER=estrogen receptor; IDC=invasive ductal carcinoma; ILC=invasive lobular 
carcinoma; ca=carcinoma; AJCC=American Joint Committee on Cancer; 
SISH=silver in situ hybridization.
endocrine therapies. 
Recently, mRNA measurement methods such as RT-PCR 
for hormonal status have been proposed as a superior alterna-
tive to IHC [15]. This study and our previous study [9] was to 
determine whether mRNA detection techniques by the Quan-
tigene2.0 assay (which use branched-chain DNA to measure 
RNA in FFPE samples) was used as the method of quantifica-
tion. In our previous study [9], we investigated the feasibility 
of gene expression of ER-alpha and PR status as an alternative 
to IHC and showed prognostic significance of PR mRNA ex-
pression but not ER-alpha mRNA. We found that the Allred 
Figure 4. Simple scatter plot, correlation between (A) ER-beta mRNA level (QuantiGene2.0) versus ER-alpha mRNA level (QuantiGene2.0) and (B) 
ER-beta mRNA level (QuantiGene2.0) versus PR mRNA level (QuantiGene2.0). ER=estrogen receptor; PR=progesterone receptor.
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Table 2. Univariate analysis results of disease-free survival and overall 
survival in surgically treated ER-positive breast cancer following endo-
crine therapy
Univariate
p-value
Disease-free survival Overall survival
Age (≥50 yr) 0.410 0.057
Tumor size 0.579 0.332
Differentiation (poor) 0.002 0.073
Histologic type (IDC) 0.871 0.687
LN metastasis (≥pN2) 0.019 0.099
Stage (III) 0.019 0.518
Chemotherapy (+) 0.830 0.952
High ER-beta mRNA 0.040 0.908
ER-beta IHC (+) 0.317 0.452
HER2 amplification (+)* 0.785 0.562
PR IHC (-) 0.007 0.492
ER=estrogen receptor; IDC=invasive ductal carcinoma; LN=lymph node; 
PR=progesterone receptor; IHC=immunohistochemistry.
*Evaluated by silver in situ hybridization.
Table 3. Multivariate analysis of disease-free survival of patients with 
breast cancer treated with endocrine therapy
Factors p-value HR 95% CI
Differentiation (poor) 0.002 5.967 1.939-18.365
LN metastasis (≥pN2) 0.035 3.985 1.103-14.392
Stage (III) 0.651 1.328 0.389-4.530
High ER-beta mRNA 0.044 4.640 1.039-20.727
PR protein (-) 0.005 5.717 1.712-19.092
HR=hazard ratio; CI=confidence interval; LN=lymph node; ER=estrogen re-
ceptor; PR=progesterone receptor.
score of ER-beta was correlated with the Allred score of PR 
and that the mRNA level of ER-beta was correlated with the 
mRNA level of PR. There have been controversial results in 
correlation between ER-beta protein and the mRNA expres-
sion level. Jarzabek et al. [16] reported a weak but positive 
correlation between mRNA and protein expression of ER-be-
ta. Most studies repeatedly found no correlation between 
mRNA and protein expression of ER-beta [17,18] and, in this 
study, there was also no correlation between ER-beta protein 
and the mRNA expression level.
We revealed the association of protein expression of ER-be-
ta with smaller tumor size in breast cancer, which was indi-
rectly supported by the theory of favorable prognostic value of 
protein expression of ER-beta [19-21]. The association of pro-
tein expression of ER-beta with smaller tumor size was previ-
ously documented [22]. Further, we revealed an independent 
association of high ER-beta-mRNA levels, quantitatively mea-
sured using the QuantiGene2.0 assay, with poor disease-free 
survival in ER-alpha positive and endocrine therapy treated 
settings. ER-beta mRNA appeared to indicate a poor response 
to treatment [23-25], which was supported by the correlation 
of ER-beta mRNA with tumor grade and the up-regulation of 
some subtypes of ER-beta during breast cancer tumorigenesis 
and tumor progression [26]; whereas positive ER-beta protein 
(even though we did not revealed the predictive value in this 
study) was thought to indicate a favorable response to anti-es-
trogen treatment [27,28]. Although there is no clear explana-
tion for these differences, the more dominant regulation of 
ER-beta protein by a degradation process, in addition to regu-
lation at a transcription level, was suggested [17].
ER-beta protein expression and mRNA expression, interest-
ingly, showed close correlation with PR protein expression and 
quantitative PR mRNA expression level, respectively, which 
represents their possible association in mechanism. However 
high ER-beta mRNA level had poor prognostic implication in 
disease-free survival in contrast to the better prognostic value 
of PR mRNA and protein expression. 
It is becoming clear that the mechanisms of action of hor-
mone receptor including ER, PR, and epidermal growth fac-
tor receptor are much more diverse and complicated than ini-
tially thought. Part of the pleiotropic of the ER pathway can 
now be explained by new discoveries regarding the intense 
cross-talk of ER with growth factor and other signaling path-
ways [29]. The expression of ER-beta mRNA level might play 
a more complicated and different role in disease recurrence in 
comparison to ER and PR.
The limits of this study are that: 1) this is a retrospective 
study and 2) we performed this study in TMA. However, the 
use of TMA has been validated in a number of tumor types by 
comparing the expression of specific proteins in a small num-
ber of TMA core biopsies with their expression in whole sec-
tions from the donor tissue. The good concordance reported 
for small sampling areas may be the result of the marker ex-
pression being abundant and/or being homogenously expressed. 
Indeed, a large study of breast cancer showed a high degree of 
concordance for hormonal receptor that a single core from rep-
resentative section identifies about 95% of the information for 
ER and 81% for PR, further, single core information yielded 
significant association or more significant associations with tu-
mor specific survival than large section analyses did [30]. So, a 
single core sample from a tumor was sufficient to identify as-
sociations between molecular alteration and clinical outcome, 
especially in the hormone receptor study of breast cancer.
As far as we know, this is the first study to assess the prog-
nostic significance of high expression of ER-beta mRNA using 
QuantiGene2.0 assay in surgically treated ER-positive breast 
cancer following hormone therapy. The high expression of 
ER-beta mRNA is an independent poor predictive marker for 
disease-free survival.86  Tae-JungKim,etal.
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2012.15.1.79
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